Why Tiny Organovo Is Giving Money to Huge Biotech Amgen

In the first half of 2017, Amgen (NASDAQ: AMGN) paid out 140 times more in dividends to its shareholders than Organovo Holdings (NASDAQ: ONVO) made in revenue -- during its entire history as a company. Of course, Amgen's market cap stands north of $120 billion, while Organovo's market cap is barely over $200 million. That kind of stark difference is to be expected.

But just a few days ago, Organovo announced that it was giving money to researchers at Amgen. Why is the tiny 3D bioprinting company handing over cash to a huge biotech that doesn't need the money?

Image source: Getty Images.

Source: Fool.com